Oveporexton significantly improves wakefulness and reduces cataplexy frequency in patients with narcolepsy type 1, according ...
Please provide your email address to receive an email when new articles are posted on . Lumryz is an extended-release, once-at-bedtime oral suspension for cataplexy or excessive daytime sleepiness in ...
Two abstracts presented at the CHEST Annual Meeting 2021 showed that patients with narcolepsy treated with once-nightly sodium oxybate, FT218, vs placebo exhibited significant improvements in sleep ...
HOUSTON -- An investigational oral drug targeting the lack of brain orexin neuropeptides that characterizes narcolepsy type 1 demonstrated safety and effectiveness for the condition in a phase IIb ...
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- Harmony Biosciences (HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for WAKIX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results